These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12574947)

  • 21. White matter proton MR spectroscopy in children with isolated developmental delay: does it mean delayed myelination?
    Fayed N; Morales H; Modrego PJ; Muñoz-Mingarro J
    Acad Radiol; 2006 Feb; 13(2):229-35. PubMed ID: 16428059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
    Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J; Francis G; Chang P;
    J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis--a quantitative T1 relaxation time mapping approach.
    Vaithianathar L; Tench CR; Morgan PS; Constantinescu CS
    J Neurol; 2003 Mar; 250(3):307-15. PubMed ID: 12638021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age.
    Chang L; Lee PL; Yiannoutsos CT; Ernst T; Marra CM; Richards T; Kolson D; Schifitto G; Jarvik JG; Miller EN; Lenkinski R; Gonzalez G; Navia BA;
    Neuroimage; 2004 Dec; 23(4):1336-47. PubMed ID: 15589098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study.
    Bendfeldt K; Kuster P; Traud S; Egger H; Winklhofer S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Matthews PM; Nichols TE; Radue EW; Borgwardt SJ
    Neuroimage; 2009 Mar; 45(1):60-7. PubMed ID: 19013533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.
    De Stefano N; Bartolozzi ML; Guidi L; Stromillo ML; Federico A
    J Neurol Sci; 2005 Jun; 233(1-2):203-8. PubMed ID: 15949506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
    Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
    Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
    Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
    Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axonal dysfunction in the deep white matter in Machado-Joseph disease.
    D'Abreu A; França M; Appenzeller S; Lopes-Cendes I; Cendes F
    J Neuroimaging; 2009 Jan; 19(1):9-12. PubMed ID: 18482370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
    Seewann A; Vrenken H; van der Valk P; Blezer EL; Knol DL; Castelijns JA; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    Arch Neurol; 2009 May; 66(5):601-9. PubMed ID: 19433660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
    Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
    J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MR spectroscopy in multiple sclerosis.
    De Stefano N; Filippi M
    J Neuroimaging; 2007 Apr; 17 Suppl 1():31S-35S. PubMed ID: 17425732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.